SLC11A2

Across TCGA pan-cancer cohorts, SLC11A2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC11A2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC11A2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SLC11A2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where SLC11A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.790	.013	12	view →
CCRCC	OS	Median	All	0.619	0.903	.024	7	view →
PDAC	OS	Median	III,IV	0.760	0.279	.017	5	view →
HNSC	OS	Tertile	IV	0.692	0.957	.035	2	view →
LSCC	DFS	Quartile	All	1.000	0.844	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC11A2–LUAD (OS)

Open the LUAD breakdown →